Creoptix announced in a press release that it has secured new investment in the company from Waters Corporation. Geoff Gerhardt, Senior Director of Corporate Development at Waters, will also be joining the Creoptix Board of Directors with immediate effect. Creoptix develops and markets analytical instruments for lab analysis in biochemistry and pharmaceutical laboratories. These can be used to study molecular interactions and facilitate new approaches in drug development as a result.
“New innovative analytical technologies are critical to accelerating biopharmaceutical therapeutic drug development processes,” comments Geoff Gerhardt. The technology developed by Creoptix opens up new possibilities for protein researchers. According to Gerhardt, Waters will help bring about the more widespread adoption of this technology by researchers. Matyas Vegh, CEO of Creoptix, rates this investment as an acknowledgement of the technology and its potential, while also providing the resources to expand the company.
Founded in 2009, Creoptix has its headquarters in Wädenswil ZH and additional offices near Boston.
The Waters headquarters are in Milford, also in the U.S. state of Massachusetts. The company’s product portfolio includes analytical instruments in the areas of high-performance liquid chromatography, mass spectrometry coupling, laboratory information management systems, rheometry, thermal analysis and microcalorimetry.
More News
Contact us
Can we put you in touch with a peer company or research institute? Do you need any information regarding your strategic expansion to Switzerland's technology and business center?
info@greaterzuricharea.com